FDA Expands Label for Imbruvica (ibrutinib), a Lymphoma Therapy, to Include Improved Survival and Safety
News
The U.S. Food and Drug Administration (FDA) recently approved an expansion to prescribing information for the kinase inhibitor Imbruvica (ibrutinib), based on improved survival, safety, and efficacy data from studies in people with chronic ... Read more